Jaka jest cena za EQRx, Inc. (EQRX)

Cena za EQRx, Inc. (EQRX) wynosi $2.34

Jaka jest kapitalizacja rynkowa dla EQRx, Inc. (EQRX)

Kapitalizacja rynkowa dla EQRx, Inc. (EQRX) wynosi $728.90M

EQRx, Inc. (EQRX) Akcje w Obiegu

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Rok	Akcje w obrocie	Zmień
Za mało danych dla podanych dat.

Rok

Akcje w obrocie

Zmień

Za mało danych dla podanych dat.

Firma	Akcje w obrocie	Różnica	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	478.91M	-	AU
Moderna, Inc. MRNA.US	396.00M	-	US
Lonza Group AG LONN.SW	-	-	CH

Firma

Akcje w obrocie

Różnica

Kraj

Vertex Pharmaceuticals Incorporated

VRTX.US

253.90M

Argenx SE

ARGX.US

62.19M

CSL Limited

CSL.AX

478.91M

Moderna, Inc.

MRNA.US

396.00M

Lonza Group AG

LONN.SW

EQRx, Inc.

EQRX

Kategoria